Debbie said the company, which will employ twenty people in its new offices, will expand its investment in
Israel in three areas: the marketing and distribution of the company's innovative technology, clinical trials
in association with the Israeli scientific establishment and cooperation with relevant Israeli ventures.
Boston Scientific has previously invested in four Israeli companies: stent-maker Medinol, Mel Medical
Enterprises, SightLine, and venture capital fund Vitalife.
The company also has exclusive distribution agreements in Japan and the U.S. with laser-maker Lumenis
(Nasdaq:LUME).
In March 2002, Medinol Ltd., in which Boston Scientific holds a 22% stake, announced the termination of its
exclusive distribution agreement, stating that Boston had consistently breached agreements between the
companies. Medinol is suing Boston Scientific in New York courts for its alleged theft of intellectual
property.
Mel Medical Enterprises was established in 1998 as a Boston subsidiary engaged in the development of
minimally invasive systems for treating both cancerous and benign growths.
Boston Scientific (NYSE: BSX) a leading American medical device maker plans to invest $100 million over
the next few years in the Israeli medical equipment and biotechnology sectors. The company recently
launched an independent Israeli representation as part of its expanding activity here, inaugurating new
offices north of Tel Aviv.
According to Boston Scientific Israel CEO Doron Debbie, the company decided to expand its activity to
Israel due its business, professional and technological potential. In June BSX celebrated the start of its
activities with a festive gathering attended by entrepreneurs and some of Israel's leading physicians.